Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing ...
Becker's Hospital Review

Pfizer gets FDA priority review for pediatric hemophilia treatment

Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab). The proposed label expansion would include patients with ...
Nasdaq

Pfizer Gets FDA Priority Review For Expanded Use Of HYMPAVZI

(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer Oncology And Rare Disease Milestones Shape Long Term Growth Prospects

Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

Pfizer Trial Updates Test Investor Views On Pipeline And Valuation

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...